Ascletis was established in 2013, and is listed on the Hong Kong Stock Exchange since 2018 (1672.HK). Ascletis focuses on the R&D and commercialization of novel medicines in non-alcoholic steatohepatitis (NASH), cancer lipid metabolism and oral checkpoint inhibitors, viral hepatitis and HIV/AIDS for unmet medical needs on a global basis. Gannex, a wholly-owned company of Ascletis，is fully dedicated to the R&D and commercialization of new drugs in the field of NASH.
Global development of novel drug candidates against three different targets – FASN, THR-beta and FXR, and three combination therapies.
A pipeline of oral inhibitors targeting FASN and a pipeline of oral PD-L1 inhibitors as the next generation checkpoint inhibitors.
Breakthrough therapies for HBV clinical cure with subcutaneously injected PD-L1 antibody - ASC22 and Pegasys® as cornerstone drugs. ASC09F has the potential to be the best-in-class protease inhibitor to treat HIV -1 infections.
Our greatest assets are our employees. Ascletis is an equal opportunity employer and focused on providing a positive work environment where courageous innovation is encouraged and expected.
Our vision is to become the most innovative world-class biomedical company. Ascletis is committed to developing and commercializing innovative drugs of NASH, cancer lipid metabolism and oral checkpoint inhibitors, viral hepatitis and HIV/AIDS , for unmet medical needs in China and globally.Our highly talented team of researchers and professionals who passionately share in this common vision.
We offer competitive salaries and benefits that reward employees for their contribution to the company. If you’re interested in learning more about what we have to offer, please email your CV to firstname.lastname@example.org. We will look to match any current and upcoming openings to your area of expertise.